TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06620809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection
Description: Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection（5×10\^9 particles）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection
Description: Extracellular vesicles placebo(5×10\^9 particles）
Study: NCT06393257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillation and Lung Expansion
Description: A novel airway clearance technology

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postural drainage
Description: A type of physical therapy used to treat respiratory diseases by changing the patient's body position so that sputum is drained down the respiratory tract so that it can be more easily expelled from the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-infective therapy
Description: Antibiotics were used in these patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-infective therapy
Description: Antibiotics were used in these patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucolytic
Description: Mucolytics were used in these patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucolytic
Description: Mucolytics were used in these patients.
Study: NCT05172869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprainguinal Performed FICB
Description: Linear ultrasound probe places above inguinal ligament sagittally, close to the femoral crease and superior-lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infrainguinal Performed FICB
Description: Linear ultrasound probe places below inguinal ligament transversally, close to the femoral crease and lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
Study: NCT06413056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive either micafungin or amphotericin B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B
Description: Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups.
Study: NCT05883774

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is applied using a transcranial magnetic stimulator with a figure-of-8 coil once per day for 10 consecutive days. rTMS is delivered to the right dorsolateral prefrontal cortex (DLPFC) at a frequency of 1 Hz for 20 minutes (1200 total pulses).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Sham-rTMS is performed in the same way as the treatment group except that the coil is rotated 90° away from the scalp.
Study: NCT04181515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo stressor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo stressor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine + Hydrocortisone
Description: Yohimbine 54mg + Hydrocortisone 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine + Hydrocortisone
Description: Yohimbine 54mg + Hydrocortisone 20mg

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Description: sham rTMS (inactive coil)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham rTMS
Description: sham rTMS (inactive coil)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active rTMS
Description: active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active rTMS
Description: active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)
Study: NCT04561011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioural Therapy(ICBT)
Description: ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
Study: NCT04707131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM-S401
Description: siRNA encapsulated in DegradaBALL®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04874376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental (Isopure 1.2.3.)
Description: Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection
Study: NCT06421753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDSS
Description: Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Electrical Stimulation During Functional Electrical Stimulation
Description: Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.
Study: NCT05540093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high power pain threshold ultrasound
Description: After explaining the procedure, and the trigger points will be marked by a physical therapist that . Then, the hand placed next to the prone position with the head in the neutral position, and the hands placed next to the body. The frequency was set to 1 MHz, and the intensity increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe will be held there for 4 s; then, the intensity was reduced by 50%, and the probe was moved over and around the trigger point. This process is done several times for three minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: the patients will receive traditional therapy in the form of postural correction exercise, active range of motion and stretching exercise for cervical muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: the patients will receive traditional therapy in the form of postural correction exercise, active range of motion and stretching exercise for cervical muscles
Study: NCT05036889

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mind.Px Report
Description: Use of Mind.Px report as a reference for potential better matching of biologics to patients.
Study: NCT04967625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: A humanized anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: A tyrosine kinase inhibitor selectively targeting VEGFR-2
Study: NCT04310943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab, 200mg, Q3W ,use until disease progression
Study: NCT05123092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided lumbar erectae spinae block
Description: One group by using ultrasound for making erectae spinae block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided lumbar erectae spinae block
Description: One group by using ultrasound for making erectae spinae block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine injection
Description: Injecting intrathecal morphine
Study: NCT05426382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A digital care solution for patients with NAFLD
Description: A digital solution that provides remote symptom monitoring and support of healthy lifestyle choices through tasks that are made more attractive with gamification and rewards.
Study: NCT06495255

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human Milk Oligosaccharides (HMOs)
Description: HMOs will be applied as a neutral-flavoured powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: will be applied as powder
Study: NCT06251258

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)
Description: Facial emotion recognition test without eye-tracking (explicit test, without time limit) and facial emotion recognition test with eye tracking (implicit test, with observation of fixation points)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)
Description: Facial emotion recognition test without eye-tracking (explicit test, without time limit) and facial emotion recognition test with eye tracking (implicit test, with observation of fixation points)
Study: NCT05024149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infrared thermography (IRT)
Description: The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infrared thermography (IRT)
Description: The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infrared thermography (IRT)
Description: The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
Study: NCT05429437

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Injectable platelet rich fibrin .
Description: i-PRF with maxillary canine retraction that will be performed two times on intervention sides according to a standardized protocol.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Injectable platelet rich fibrin .
Description: i-PRF that will be performed four times on intervention sides according to a standardized protocol.
Study: NCT06289634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Man-made sounds
Description: Participants will be asked to listen to the assigned sounds (relaxing music) for 30 minutes a day for 15 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural sounds
Description: Participants will be asked to listen to the assigned sounds (birds, ocean, wind) for 30 minutes a day for 15 days.
Study: NCT04785326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMB-3115
Description: 45mg or 90mg dose subcutaneous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMB-3115
Description: 45mg or 90mg dose subcutaneous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara
Description: 45mg or 90mg dose subcutaneous administration
Study: NCT04878016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZKAB001
Description: Patients will receive ZKAB001 5mg/kg administered by IV infusion every 21days，

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo administered by IV infusion every 21days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
Study: NCT03976895

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Supine position (SP)
Description: Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.~Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone position (PP)
Description: Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.~Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis.
Study: NCT06072820

Intervention type: DEVICE
Group type: OTHER
Intervention: Salivary Sampling
Description: Inclusion visit: After signature of the informed consent, all subjects will perform 3 consecutive Endotest® Diagnostic during the visit and 1 at-home.~Circadian circle visit: 6 included subjects will be asked to come back for a full day. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit.~Repeatability-intermediate fidelity-stability-interferences visit: a maximum of 16 included subjects will be asked to come back for this visit. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit.
Study: NCT05404867

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: fMRI scan for 1 hour

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: fMRI scan for 1 hour
Study: NCT05123092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine injection
Description: Injecting intrathecal morphine
Study: NCT05307016

Intervention type: DIAGNOSTIC_TEST
Intervention: Two dimensional ultrasonography power and color doppler
Description: transabdominal and transvaginal two-dimensional power Doppler ultrasound volumes of the placental bed were obtained according to a predefined protocol with the participant in a semi-recumbent position and a full bladder using a RAB4-8-D 3D/4D curved array abdominal transducer (4-8.5 MHz) on a Voluson E8. Predetermined machine settings were used. To allow for differences in attenuation of the power Doppler signal resulting from variation in placental site and maternal adiposity.~Intraoperative staging of degree of placental invasion will be done according to clinical grading system by Collins et al., 2015.~Specimens obtained from patients who underwent hysterectomy or resection of segment of anterior uterine wall in cases with anterior placenta previa will be immersed in formalin 10% concentration and will be sent for histopathological evaluation that will be done by the same pathologist.
Study: NCT06105749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contrast-enhanced mammography
Description: Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
Study: NCT05116865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study: NCT05784974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
Study: NCT05545631

Intervention type: OTHER
Intervention: no intervention
Description: no intervention in this study

Intervention type: OTHER
Intervention: no intervention
Description: no intervention in this study
Study: NCT05030194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Participants engage in 30 minutes of an oral nicotine product. In those 30 minutes the product can be used as much or as little as preferred.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Participants engage in 30 minutes of an oral nicotine product. In those 30 minutes the product can be used as much or as little as preferred.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nicotine Pouch
Description: Participants will be instructed to place a 6mg nicotine pouch in their mouth between gum and lip for up to 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nicotine Pouch
Description: Participants will be instructed to place a 6mg nicotine pouch in their mouth between gum and lip for up to 30 minutes.
Study: NCT06546189

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OMNi BiOTiC® 41167
Description: The product OMNi BiOTiC® 41167 contains lactobacillus strains

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06004609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Description: Low-level laser therapy (LLLT), three time each week, 10 minutes each time, during the first 8 weeks of the treatment trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy will be applied three time each week, for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Conventional physical therapy will be applied three time each week, for 12 weeks
Study: NCT05487456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P4M3 CA35
Description: Ad libitum use of P4M3 with CA35 cartridges

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P4M3 CM35
Description: Ad libitum use of P4M3 with CM35 cartridges

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Ad libitum use of subject's own preferred brand of cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence
Description: Abstention from cigarette smoking
Study: NCT05923775

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted third molar surgey
Description: The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Impacted third molar surgey
Description: The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted third molar surgey
Description: The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted third molar surgey
Description: The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.